

REMARKS

Claims 36-39, 89, 90 are pending. No claims are withdrawn. Claims 1-35, 40-88 have been canceled. New claims 89,90 have been added.

Support for the amendments to claim 36 is found at page 14, lines 14-26, and FIGS. 5, 26 and 27 of the as-filed specification.

Support for the amendments to claims 37-39 is found at page 15, line 30 to page 16, line 2 of the as-filed specification.

Support for new claim 89 is found at FIGS. 5, 26 and 27 of the as-filed specification.

Support for new claim 90 is found at page 14, lines 15-16 of the as-filed specification.

The specification stands objected to as failing to provide proper antecedent basis for the claimed subject matter, as it fails to point out that the alpha angle is called the “output port angle” as referred to in the claim.

Applicants have amended claims 37-39 to simply recite “angle α ”, which is consistent with the as-filed application.

Claims 36-38 stand rejected as anticipated by US Patent No. 5,190,524 (“Wex”).

Applicants submit that the as-amended claims are patentable over Wex. Claim 36 currently requires delivery syringes having plungers therein attached to the input ports. Wex does not teach delivery syringes having plungers therein attached to the input ports. Therefore, the present anticipation rejection should be withdrawn.

Claim 39 stands rejected as being unpatentable over US Patent No. 5,190,524 (“Wex”).

As claim 39 depends from claim 36, it is patentable over Wex for the same reasons as discussed above for claim 36.


New claim 89 contains independent patentability. Claim 89 further requires that the plunger of each delivery syringe extends upward from the upper surface. This feature allows the user to place the device on a flat table top and stably push downward upon the plungers in order to actuate the device and push the fluids contained therein into the fluid retention chamber. In contrast, pushing upon the laterally-oriented openings of the input ports of Wex does not produce such a stable result. Therefore, claim 89 provides an advantage over Wex.

New claim 90 contains independent patentability. Claim 90 further requires that the input ports respectively contain PRP and thrombin. Wex does not teach or suggest that the input ports contain PRP and thrombin.

In addition, please provide any additional extensions of time which may be necessary and charge any fees which may be due to Deposit Account No. 10-0750, but do not include any payment of issue fees.

Should there be any remaining or further questions, the Examiner is requested to place contact the undersigned directly.

Respectfully submitted,

 2.28.06

Thomas M. DiMauro
Attorney for Applicants
Reg. No. 35,490
Johnson & Johnson
1 Johnson & Johnson Plaza
New Brunswick, NJ
(508) 880-8401